News Center

Home page

Peak Report

News reports

Announcement on Subsidiary Obtaining Notice of Approval for Drug Clinical Trials

Release time:

2021-05-20

Securities Code: 600668 Securities Abbreviation: Jianfeng Group No: pro 2021-001

Zhejiang Jianfeng Group Co., Ltd.

Announcement on Subsidiaries Obtaining Drug Clinical Trial Approval Notice

The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .

Important Note:

Company's approval notice for drug clinical trials will not have a significant impact on the company's recent operating results.
Risk Warning: Due to the particularity of drug research and development, the pre-development of drugs and the long cycle and many links of products from development, clinical trials to production are susceptible to some uncertain factors, clinical trial progress, There are many uncertainties in the results and the future product market competition situation.
1. Summary
Recently, Zhejiang Erying Pharmaceutical Co., Ltd. (hereinafter referred to as "Erying Company") and , the controlling subsidiary of Zhejiang Jianfeng Pharmaceutical Co., Ltd., the controlling subsidiary of the Company, received the Notice of Approval for Clinical Trials of Drugs approved and issued by the State Drug Administration. The relevant details are hereby announced as follows:
2. drug basic information content
drug name: acetaminophen suppository
English name: Paracetamol Suppositories
dosage form: suppository
application classification: generic drug application
specification: 75mg , 125mg
registration classification: chemical drugs category 3
applicant: Zhejiang erying drug co., ltd.
approval conclusion: "according to the the People's Republic of China drug administration law and relevant regulations, after examination, the acetaminophen suppository accepted on 2020 5 February 13 meets the relevant requirements for drug registration, it is recommended that the bioequivalence study of this product be carried out in healthy adults with a single fasting dose, and that the study of BE be exempted under different specifications to meet pharmaceutical requirements."
3. Drug Research and Development and Investment
Acetaminophen Suppository is an antipyretic analgesic developed by Erying Company. Its registered classification belongs to chemical drug 3 . Acetaminophen Suppository is indicated for fever caused by common cold or influenza in children, and is also used for relieving mild to moderate pain such as headache, arthralgia, migraine, toothache, myalgia and neuralgia. As of the date of this announcement, the accumulated research and development expenses and technical investment of the project totaled about RMB ,788.09 . Market Situation of
4. Similar Drugs
Acetaminophen Suppository was first developed by German Bene Company and listed in Germany in 1960 . In 2019 , the dosage of German acetaminophen Suppository was about 1.08 .6 billion tablets (data source: IMS ). At present, paracetamol suppositories of infant specifications have been listed in many countries in the world. At present, paracetamol suppositories of 125 mg , 150 mg , 300 mg and 600 mg have been listed in China, of which 125 mg and 150 mg are used for fever caused by common cold or influenza in children aged 1-6 , no paracetamol suppositories exist for infants and young children aged 0-1 years. Acetaminophen suppository (75 mg ) developed by Erying Company is suitable for antipyretic and analgesic treatment for infants aged 0-1 years old in China. Acetaminophen suppository (125 mg ) is suitable for infants aged 6 months to 2 years old (administered according to age and weight). Scientifically administered acetaminophen suppository will be provided for infants aged 0-2-2-116 years old. Approval Procedures to Be Performed for Listing of 5. Products
Er Ying Company will conduct clinical trials (bioequivalence studies) according to the requirements of the Notice of Approval of Drug Clinical Trials. After the clinical trials are completed, it will apply for production. After passing the review and approval of the State Food and Drug Administration and obtaining the approval documents for drug production, it can produce
products and go on sale. 6. Impact on Listed Companies and Risk Tips
The company's approval notice for drug clinical trials will not have a significant impact on the company's recent operating results. Due to the particularity of drug research and development, the pre-development of drugs and the long cycle and many links from development, clinical trials to production of products are easily affected by some uncertain factors. There are many uncertainties in the progress and results of clinical trials and the future product market competition situation. The company will be based on the progress of research and development in a timely manner to fulfill the obligations of information disclosure, so that the majority of investors pay attention to investment risks.
hereby announce
Zhejiang Jianfeng Group Co., Ltd.

January 6, 2001

More information

Chairman Jiang Xiaomeng was named "Fengyun Zhejiang Merchants"

On the evening of January 13, the 2021 "Fengyun Zhejiang Merchants" award ceremony was held in Hangzhou. Ten outstanding Zhejiang businessmen, including Jiang Xiaomeng, chairman of the group company, won the honor. The annual "Fengyun Zhejiang Merchants" selection activity is guided by the Propaganda Department of the Zhejiang Provincial Committee of the Communist Party of China, sponsored by Zhejiang Radio and Television Group, and co-organized by Zhejiang Economic Television, Qianjiang Evening News and Zhejiang Merchants Magazine. Provincial Department of Economics and Information Technology, Provincial Department of Science and Technology, Provincial Department of Commerce, Provincial Federation of Industry and Commerce and many other units jointly co-organized. Since its establishment in 2003, it has been held for 18 sessions, and more than 180 "Fengyun Zhejiang businessmen" have been selected. They are all successful models and fresh samples of Zhejiang's economic development.

2022

01-17

Peak re-listed China's top 100 building materials enterprises

China Building Materials Enterprise Management Association recently released a series of lists of "2021 Top 500 Chinese Building Materials Enterprises", and Jianfeng Group ranked among the "2021 Top 100 Chinese Building Materials Enterprises". This series of lists has been released every year since 2002, and has received extensive attention and active participation from governments at all levels, building materials authorities and building materials companies. It has become a vane of China's building materials industry. Since participating in the selection of the list, the peak has been ranked among the top 100 building materials enterprises in China for many years.

2022

01-04

Hubei "Wisdom and Energy Saving" Focus on Daye Peak

On the morning of December 3, more than 180 people from relevant competent departments at all levels and key energy consuming units in Hubei Province gathered in Daye Jianfeng cement company to visit and understand Daye Jianfeng's practice and experience in intelligent energy conservation. On the same day, the provincial smart energy-saving training meeting organized by the Hubei Provincial Development and Reform Commission was held in daye city. daye peak was the only visiting enterprise arranged for the meeting.

2021

12-13

Daye Peak passed the intellectual property management system certification.

Recently, Daye Jianfeng Cement Company received the intellectual property management system certification certificate issued by Guozhi (Beijing) Certification Company. This is also the first system certificate obtained by the company to implement the intellectual property management standard certification. In recent years, Daye Jianfeng has actively mobilized employees to carry out technological innovation, invention and creation, and timely summarized technological achievements and filed patents. Up to now, it has obtained 31 invention patents and utility model patents. At the same time, Daye's concept of the creation, application, management and protection of intellectual property rights is also increasing, and it continues to increase the promotion of new products and new technologies with high value-added intellectual property rights, and enhance the value of corporate intangible assets. Intensity. The passing of this system certification can not only obtain government incentives and funding, but also the basic conditions for intellectual property work and the prerequisite for applying for related projects.

2021

12-13

The Group Party Committee organized the Sixth Plenary Session of the 19th Central Committee to preach the spirit.

In order to quickly set off an upsurge of studying and implementing the spirit of the Sixth Plenary Session of the 19th Central Committee of the Party, and effectively unify thoughts and actions into the decision-making and deployment of the Party Central Committee with Comrade Xi Jinping as the core, and earnestly learn in the depths, seek new places, and do In practice, on December 1, the party committee of the group company held a spiritual lecture at the Sixth Plenary Session of the 19th Central Committee, which was delivered by Jiang Xiaomeng.

2021

12-13

Group Party Committee to Learn the Spirit of the Sixth Plenary Session of the 19th Central Committee

On the afternoon of November 18, the Party Committee of the Group held a special meeting to learn the spirit of the Sixth Plenary Session of the 19th CPC Central Committee and make arrangements for in-depth study. The Sixth Plenary Session of the 19th Central Committee of the Communist Party of China is an important meeting of overall and historical significance held at the historical intersection of the "two centenary" goals on the occasion of celebrating the centenary of the Communist Party of China. The "Resolution of the Central Committee of the Communist Party of China on the Major Achievements and Historical Experience of the Party's Hundred Years of Struggle" approved by the plenary session is a Marxist programmatic document that inherits the past and the future. It is also an action guide to learn from history, create the future, and realize the great rejuvenation of the Chinese nation. At the special meeting, Jiang Xiaomeng, Secretary of the Party committee of the group, and all the members of the Party committee, from the great achievements, historical significance and historical experience created by the party's 100 year history, since the 18th National Congress of the Communist Party of China, it has adhered to the party's overall leadership, comprehensive and strict governance of the party, economic construction, comprehensive deepening of reform and opening up, political construction, comprehensive rule of law, cultural construction, social construction, ecological civilization construction, national defense and military construction, and maintenance of national security., Adhere to the "one country, two systems" and promote the reunification of the motherland, diplomatic work and other 13 important achievements, comprehensively interpret and study the resolutions of the plenary session.

2021

11-22

< 1...7 8 9...61 > 跳转到页